---
title: Tezepelumab in patients with allergic and eosinophilic asthma
date: '2023-12-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38146651/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231227170859&v=2.18.0
source: heidelberg[Affiliation]
description: Asthma is a heterogeneous disease commonly driven by allergic and/or
  eosinophilic inflammation, both of which may be present in severe disease. Most
  approved biologics for severe asthma are indicated for specific phenotypes and target
  individual downstream type 2 components of the inflammatory cascade. Tezepelumab,
  a human monoclonal antibody (immunoglobulin G2λ), binds specifically to thymic stromal
  lymphopoietin (TSLP), an epithelial cytokine that initiates and sustains allergic
  ...
disable_comments: true
---
Asthma is a heterogeneous disease commonly driven by allergic and/or eosinophilic inflammation, both of which may be present in severe disease. Most approved biologics for severe asthma are indicated for specific phenotypes and target individual downstream type 2 components of the inflammatory cascade. Tezepelumab, a human monoclonal antibody (immunoglobulin G2λ), binds specifically to thymic stromal lymphopoietin (TSLP), an epithelial cytokine that initiates and sustains allergic ...